Blood cell study aims to predict transplant complications
NCT ID NCT02194868
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 57 people who had a stem cell transplant for blood cancer. Researchers wanted to see if certain immune cells (iNKT cells) could help predict the risk of graft-versus-host disease (GVHD), a serious side effect. They measured these cells in the blood and the transplant itself to create a tool for doctors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Necker
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test outsmart deadly fungal infections in blood cancer?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Can a lower drug dose make stem cell transplants safer?
- Plant pigment could soothe Radiation's harsh side effect in blood cancer treatment
- New Antibody-Drug conjugate targets Hard-to-Treat cancers